Kampouri Eleftheria, Croxatto Antony, Prod'hom Guy, Guery Benoit
Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Institute of Microbiology, Department of Medical Laboratory and Pathology, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
J Clin Med. 2021 Jan 20;10(3):389. doi: 10.3390/jcm10030389.
is an increasingly common pathogen both within and outside the hospital and is responsible for a large clinical spectrum from asymptomatic carriage to complicated infection associated with a high mortality. While diagnostic methods have considerably progressed over the years, the optimal diagnostic algorithm is still debated and there is no single diagnostic test that can be used as a standalone test. More importantly, the heterogeneity in diagnostic practices between centers along with the lack of robust surveillance systems in all countries and an important degree of underdiagnosis due to lack of clinical suspicion in the community, hinder a more accurate evaluation of the burden of disease. Our improved understanding of the physiopathology of CDI has allowed some significant progress in the treatment of CDI, including a broader use of fidaxomicine, the use of fecal microbiota transplantation for multiples recurrences and newer approaches including antibodies, vaccines and new molecules, already developed or in the pipeline. However, the management of CDI recurrences and severe infections remain challenging and the main question remains: how to best target these often expensive treatments to the right population. In this review we discuss current diagnostic approaches, treatment and potential prevention strategies, with a special focus on recent advances in the field as well as areas of uncertainty and unmet needs and how to address them.
无论是在医院内还是医院外,它都是一种日益常见的病原体,可导致从无症状携带到伴有高死亡率的复杂感染等广泛的临床症状。尽管多年来诊断方法有了很大进展,但最佳诊断算法仍存在争议,且没有一种单一的诊断测试可作为独立测试使用。更重要的是,各中心诊断实践的异质性,以及所有国家缺乏强大的监测系统,再加上社区中因缺乏临床怀疑而导致的重要程度的诊断不足,阻碍了对疾病负担进行更准确的评估。我们对艰难梭菌感染(CDI)病理生理学的深入了解,已在CDI治疗方面取得了一些重大进展,包括更广泛地使用非达霉素、对多次复发使用粪便微生物群移植,以及已经开发或正在研发的包括抗体、疫苗和新分子在内的新方法。然而,CDI复发和严重感染的管理仍然具有挑战性,主要问题仍然是:如何以最佳方式将这些通常昂贵的治疗针对合适的人群。在本综述中,我们讨论了当前的诊断方法、治疗和潜在的预防策略,特别关注该领域的最新进展以及不确定性和未满足需求的领域,以及如何解决这些问题。